Comparison of 10‐day levofloxacin bismuth‐based quadruple therapy and levofloxacin‐based triple therapy for <i>Helicobacter pylori</i>

Wu, Tzung-Shiun; Hsu, Ping‐I; Kuo, Chao‐Hung; Hu, Huang‐Ming; Wu, I-Chen; Wang, Sophie S.W.; Chen, Yen-Hsu; Wu, Deng‐Chyang; Su, Wei‐Wen; Kuo, Fu‐Chen

doi:10.1111/1751-2980.12498

Cited by 17 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To increase the success rates of quinolone triple therapies, some (379)(380)(381) . studies have added bismuth salt to the regimen, which provided good results for eradication (398,399) . Quadruple bismuth therapy (PPI, bismuth, tetracycline, and metronidazole) is usually recommended during retreatment, with eradication rates approaching 80% (392) .…”

Section: Level Of Evidence: 2a Grade Of Recommendation: Bmentioning

confidence: 99%

Ivth Brazilian Consensus Conference on Helicobacter Pylori Infection

Coelho

Marinho

Genta

et al. 2018

Arq. Gastroenterol.

View full text Add to dashboard Cite

Significant progress has been obtained since the III Brazilian Consensus Conference on H. pylori infection held in 2012, in Bento Gonçalves, Brazil, and justify a fourth meeting to establish updated guidelines on the current management of H. pylori infection. Therefore, the Núcleo Brasileiro para Estudo do Helicobacter pylori e Microbiota (NBEHPM), association linked to Brazilian Federation of Gastroenterology (FBG) held its fourth meeting again in Bento Gonçalves, RS, Brazil, on August 25-27, 2017. Twenty-six delegates, including gastroenterologists, endoscopists, and pathologists from the five regions of Brazil as well as one international guest from the United States, participated in the meeting. The participants were invited based on their knowledge and contribution to the study of H. pylori infection. The meeting sought to review different aspects of treatment for infection; establish a correlation between infection, dyspepsia, intestinal microbiota changes, and other disorders with a special emphasis on gastric cancer; and reassess the epidemiological and diagnostic aspects of H. pylori infection. Participants were allocated into four groups as follows: 1) Epidemiology and Diagnosis, 2) Dyspepsia, intestinal microbiota and other afections, 3) Gastric Cancer, and, 4) Treatment. Before the consensus meeting, participants received a topic to be discussed and prepared a document containing a recent literature review and statements that should be discussed and eventually modified during the face-to-face meeting. All statements were evaluated in two rounds of voting. Initially, each participant discussed the document and statements with his group for possible modifications and voting. Subsequently, during a second voting in a plenary session in the presence of all participants, the statements were voted upon and eventually modified. The participants could vote using five alternatives: 1) strongly agree; 2) partially agree; 3) undecided; 4) disagree; and 5) strongly disagree. The adopted consensus index was that 80% of the participants responded that they strongly or partially agreed with each statement. The recommendations reported are intended to provide the most current and relevant evidences to management of H. pylori infection in adult population in Brazil.

show abstract

Section: Level Of Evidence: 2a Grade Of Recommendation: Bmentioning

confidence: 99%

Ivth Brazilian Consensus Conference on Helicobacter Pylori Infection

Coelho

Marinho

Genta

et al. 2018

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…In another study, the e cacy of adding bismuth to a levo oxacin-based triple regimen (rabeprazole, bismuth, amoxicillin, and 500 mg of levo oxacin daily) assessed. The results revealed no further signi cant eradication rat (67.6%), but no more ADRs were noted [40].…”

Section: Discussionmentioning

confidence: 82%

The Efficacy, Safety, And Tolerability of Levofloxacin Quadruple Therapy For Helicobacter Pylori Eradication: A Randomized, Double-Blind Clinical Trial

Mansour‐Ghanaei

Masihypour

Fathalipour

et al. 2021

Preprint

View full text Add to dashboard Cite

The incidence of microbial resistance is increasing, and new rescue regimens are needed in order to treat Helicobacter pylori (H. pylori) infection. To evaluate the efficacy, safety, and tolerability of levofloxacin based quadruple therapies in the eradication of H. pylori. In a randomized, double-blind clinical trial, 220 patients with dyspepsia and H. pylori infection were randomly assigned to receive either bismuth subcitrate 240 mg, pantoprazole 20 mg, amoxicillin 1000 mg twice a day, and levofloxacin 500 mg daily for seven days (BPAL-7), or ten days (BPAL-10). The eradication of H. pylori was evaluated two months after the end of treatment, and adverse drug reactions (ADRs) were assessed during the intervention. According to intention-to-treat and per-protocol, the eradication rate was significantly lower in the BPAL-7 regimen 49.1 % (95 % CI: 39.3-57.8) and 47.6 % (95 % CI: 39.7-58.4), respectively compared to the BPAL- 10 regimen 62.7 % (95 % CI: 53.6-72.8) and 62.4 % (95 % CI: 55.1-72.8), respectively. The incidence of ADRs was not statistically significant between BPAL-7 (33.6 %) and BPAL-10 (36.7 %) groups. Although the ADRs were negligible in both groups, these regimens could not be an ideal alternative therapy for H. pylori because of low eradication rates compared to standard regimens.Trial registration: The study reviewed and approved by the Iranian Registry of Clinical Trials (IRCT201406141155N19).

show abstract

“…A further study from Taiwan demonstrated higher eradication rates with levofloxacin‐based concomitant therapy (96.4%) compared to sequential therapy (81.4%) . The addition of bismuth to levofloxacin‐based triple therapy, however, in areas with low levofloxacin resistance does not confer any further benefit …”

Section: Fluoroquinolonesmentioning

confidence: 99%

“…34 The addition of bismuth to levofloxacin-based triple therapy, however, in areas with low levofloxacin resistance does not confer any further benefit. 35 A retrospective study assessing the utility of a moxifloxacinbased triple therapy reported eradication rates of 80% following hybrid therapy failure. 36 Quinolone-based rescue therapies are more successful in bismuth-containing quadruple therapies, with longer duration (10-14 days) than 7-day treatment.…”

Section: Fluoroquinolone Smentioning

confidence: 99%

Treatment of Helicobacter pylori infection in 2018

et al. 2018

View full text Add to dashboard Cite

Treatment options for the eradication of Helicobacter pylori continue to evolve. There have been many guidelines for H. pylori treatment published, which may lead to some confusion. However, most are in agreement with the most recent iteration of the Maastricht treatment guidelines. Triple therapy is still the most frequently used treatment, especially in areas of low clarithromycin resistance. Its best results are achieved when taken for a minimum of 10 days and with high-dose acid suppression. Quadruple therapy is gaining in popularity particularly in areas with increasing resistance to standard triple therapy. Whether three antibiotics, or bismuth and two antibiotics are used, excellent eradication rates are achieved, albeit with increased side effects. Levofloxacin second-line therapy is widely used; however bismuth, when available, is an increasingly successful option. Sequential therapy is challenging in terms of compliance and is no longer recommended. This past year witnessed a notable increase in the number of studies based on antimicrobial susceptibility testing and tailored eradication therapy, reflecting the role of culture-guided treatment, which may well represent the future of H. pylori treatment and prevent the inappropriate use of antibiotics.

show abstract

Comparison of 10‐day levofloxacin bismuth‐based quadruple therapy and levofloxacin‐based triple therapy for Helicobacter pylori

Cited by 17 publications

References 21 publications

Ivth Brazilian Consensus Conference on Helicobacter Pylori Infection

Ivth Brazilian Consensus Conference on Helicobacter Pylori Infection

The Efficacy, Safety, And Tolerability of Levofloxacin Quadruple Therapy For Helicobacter Pylori Eradication: A Randomized, Double-Blind Clinical Trial

Treatment of Helicobacter pylori infection in 2018

Contact Info

Product

Resources

About